S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

$285.80
-4.12 (-1.42 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$285.21
Now: $285.80
$291.04
50-Day Range
$248.78
MA: $261.82
$289.89
52-Week Range
$196.29
Now: $285.80
$294.57
Volume601,151 shs
Average Volume508,133 shs
Market Capitalization$24.52 billion
P/E Ratio67.09
Dividend YieldN/A
Beta0.72
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.21 billion
Cash Flow$5.37 per share
Book Value($0.11) per share
Price / Book-2,598.18

Profitability

Net Income$377.03 million

Miscellaneous

Employees8,377
Market Cap$24.52 billion
Next Earnings Date1/31/2020 (Confirmed)
OptionableOptionable

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.


Stock Trades Or Predictions (Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, October, 31st. The company reported $1.24 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.10. The company had revenue of $605.30 million for the quarter, compared to analyst estimates of $597.09 million. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. IDEXX Laboratories's quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.05 EPS. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY20 earnings guidance on Thursday, October, 31st. The company provided EPS guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

What price target have analysts set for IDXX?

6 brokerages have issued 1-year target prices for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' share price to reach $293.33 in the next year. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:
  • 1. According to Zacks Investment Research, "Shares of IDEXX have outperformed its industry in a year’s time. IDEXX exited the third quarter on an impressive note with better-than-expected numbers. The company’s solid organic revenue growth is encouraging. The top line was driven by strong sales at the CAG and LPD businesses. Specifically, the company witnessed sturdy gains from CAG Diagnostics in the quarter. It also witnessed strong performances in IDEXX VetLab consumables, reference laboratory diagnostic and consulting, and moderately robust growth in rapid assay products’ revenues globally. The global adoption of its latest products and services, including the rapid expansion of Catalyst installed base, and increased utilization of the Fecal Dx Antigen Panel and IDEXX SDMA test, is another driving factor. However, a lowered EPS view for 2019 is a concern." (1/3/2020)
  • 2. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)

Has IDEXX Laboratories been receiving favorable news coverage?

News articles about IDXX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IDEXX Laboratories earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for IDEXX Laboratories.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decrease in short interest in the month of December. As of December 13th, there was short interest totalling 1,310,000 shares, a decrease of 10.3% from the November 28th total of 1,460,000 shares. Based on an average trading volume of 463,700 shares, the days-to-cover ratio is currently 2.8 days. Approximately 1.6% of the shares of the stock are short sold. View IDEXX Laboratories' Current Options Chain.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Adobe (ADBE), Alibaba Group (BABA), Home Depot (HD), Mastercard (MA), Intuitive Surgical (ISRG), Micron Technology (MU) and ServiceNow (NOW).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Welch & Forbes LLC (0.21%), Chicago Capital LLC (0.11%), Nisa Investment Advisors LLC (0.07%), Woodstock Corp (0.05%), Spence Asset Management (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Cribstone Capital Management LLC, State of Alaska Department of Revenue, Calamos Wealth Management LLC and Tuttle Tactical Management. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Johanson Financial Advisors Inc., Pensionfund DSM Netherlands, Pensionfund Sabic, Cerebellum GP LLC, Baxter Bros Inc., Red Spruce Capital LLC and Washburn Capital Management Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $285.80.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $24.52 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is http://www.idexx.com/.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  771
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel